Aroundtown SA

  • WKN: A2DW8Z
  • ISIN: LU1673108939
  • Land: Luxemburg

Nachricht vom 25.10.2021 | 11:24

Aroundtown SA: Release of a capital market information

Aroundtown SA (IRSH)
25-Oct-2021 / 11:24 CET/CEST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Disclosure pursuant to Art. 5 Sec. 1 lit. b) and Sec. 3 of the Regulation (EU) No 596/2014 (MAR) in conjunction with Art. 2 Sec. 2 and Sec. 3 of the Commission Delegated Regulation (EU) No 2016/1052 - 31 Interim Announcement

In the period from 18 October 2021 up to and including 22 October 2021, Aroundtown SA bought back a total of 3,125,900 shares of Aroundtown SA under the share buyback program; on 25 March 2021, Aroundtown SA disclosed pursuant to Art. 2 Sec. 1 of the Commission Delegated Regulation (EU) No 2016/1052 the beginning of the share buyback on 26 March 2021.

The overall volume of the shares bought back daily and the daily volume-weighted average stock market prices of the shares are as follows:

Date Aggregate volume Weighted average price (EUR)
18.10.2021 480,742 6.01265
19.10.2021 720,742 6.06401
20.10.2021 508,699 6.02790
21.10.2021 710,522 6.14250
22.10.2021 705,195 6.10033
In total 3,125,900 6.07627
 

The purchase of the Aroundtown SA shares was carried out by a bank commissioned by Aroundtown SA and exclusively via the Frankfurt Stock Exchange (XETRA trading).

More detailed information pursuant to Art. 5 Sec. 1 lit. b) and Sec. 3 of the Regulation (EU) No 596/2014 in conjunction with Art. 2 Sec. 2 and Sec. 3 of the Commission Delegated Regulation (EU) No 2016/1052 is available on the internet at https://www.aroundtown.de/investor-relations/equity/share/share-buyback/.

Berlin, 25 October 2021

Aroundtown SA

Board of Directors




show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktueller Webcast

Adler Group S.A.

Nine-Month
Investor Call
Q3 2021

30. November 2021

Aktuelle Research-Studie

Original-Research: Gold Mountain Mining Corp. (von hanseatic stock publishing UG (haftungsbeschränkt)): Gold Mountain Mining Corp.

29. November 2021